Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Paclitaxel/Carboplatin in First-Line Ovarian Cancer
NCT00390611Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Oct 2006
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in ovarian cancer (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Progression-free Survival at 2 years. Started Oct 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00390611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390611.